We are constantly searching for new technologies pertaining to our indications that enable us to identify and develop new drugs.





By developing innovative next generation biotherapeutics to address unmet medical needs, we’re dedicated to continually improving our offerings of therapeutic products for complex medical conditions. At the same time, we’re invested in research and development of new treatments and in expanding scientific and clinical knowledge that will improve patient care and outcomes.

    • (Antibody) phage display
    • Immunization techniques
    • B-cell technologies
    • (Antibody) yeast display
    • Novel antibody formats
    • Bispecific antibodies
    • Tolerization
    • Antibodies to GPCRs and Ion channels
    • Microfluidics technologies
    • Mammalian cell expression (antibodies and other proteins)
    • Production cell lines for biologics
    • Technologies for protein purification
    • Next generation sequencing
    • Analytics for characterization of biological drug candidates – mass spectrometry, glycosylation, epitope mapping, functional assays, developability assays
    • In silico and HT in vitro assays to predict/test solubility, viscosity and aggregation behaviour of antibodies /biologics
    • Site specific conjugation of ADCs
    • DNA library construction
    • Assays for target validation and HT assays
    • Immunological and reporter gene assays





    Preclinical cancer models (cell lines / in vivo models):

    • Defined pathology (solid and hematological tumors) preferably outside the big indications or with equipped with special features

    • Available molecular data (growth characteristics, gene expression, mutation profile, copy number etc.- all on whole genome level)

    • Available clinical record, treatments, description/available starting material, actual status (passage number), sensitivity/resistance towards standard of care drugs

    • If a cell line: possibility for in vivo use





    We are generally interested in technologies useful for the development of predictive, prognostic, safety, and pharmacodynamic markers in all our indications. Furthermore, we are interested in markers that are technically validated and fit-for-purpose in clinical settings to support our drug development programs in all indications.


      Identification of molecular and quantifiable biomarkers:

      Heart Diseases:

      Biomarkers which represent pathomechanisms or a certain degree of a pathomechanism (e.g. extracellular matrix turnover and fibrosis, microcirculation, cardiomyocyte injury, metabolic remodeling, mitrochondrial dysfunction) in heart failure.

      Kidney Diseases:

      Biomarkers which represent pathomechanisms or a certain degree of a pathomechanism (e.g. kidney fibrosis, inflammation) in kidney diseases. Preferred: circulation/blood-based or urinary biomarker

      Vascular Diseases:

      Biomarkers which represent pathomechanisms or a certain degree of a pathomechanism (e.g. fibrosis, inflammation) in vascular/ lung diseases. Preferred: circulation/blood-based biomarker

      Hemostatic and acute organ disorders:

      Biomarkers which can be used for inclusion or exclusion of patients in acute / critical care disorders (ARDS, AKI, DIC, on the ICU)

      Identification of analytical devices to continuously monitor vital functions, which represent pathomechanisms or a certain degree of a pathomechanism in all indications.





      We are interested in tissue samples to support our research dealing with proliferative diseases:

        • Prostate (in particular the process of metastasis), hematological tumors, breast, colon, lung, ovarian, as well as mesothelioma, gastric, liver, head & neck, melanoma, bladder, and triplenegative breast (TNB) cancer, hematological malignancies, pediatric tumors

        • Refractory to targeted therapy or immunotherapy (e.g. Tarceva-resistant lung CA, Herceptinresistant mamma CA, Avastin-resistant/insensitive tumors, Taxane-resistant tumor models, PD-1/PD-L resistant tumors)

        • Tissue of non-responders or patients becoming refractory to immune checkpoint inhibitors

        • Under-, post- or refractory to standard therapy according to guidelines, ideally matched to pre-therapy samples

        • Tissue from endometriosis / adenomyosis uteri, uterine fibroids / PCOS patients





        Bayer’s goal with its Disease Genomic Working Group is to sustainably support cardiology/ophthalmology and gynecology research by determining the genetic basis of phenotypic variations of related diseases. This innovative approach improves the understanding of the underlying disease biology and pathophysiology, the identification of genes and related pathways for the use as therapeutic targets and/or biomarkers, as well as for patient stratification.

          • Case/control studies in patients with well-defined cardiovascular, ophthalmic or gynecological phenotypes

          • Epidemiological cardiovascular studies

          • SNP-arrays, whole genome/exome sequencing – platforms in use

          • IT/Software-solutions for Bayer´s Cardiogenomic Browser to integrate public and internal data in Asian-Pacific Area

          • Novel analysis tools for genome-wide association study and whole genome/exome sequence data analysis, especially tools for genetic risk variation pattern to be predictive for disease development and/or progression and/or stratification of high-risk patients in epidemiological cardiovascular studies

          • In vitro molecular biology/biochemistry (assay development) – access to human iPS cells from genetically/phenotypically defined patients, cultivation and differentiation of iPS cells into cardiovascular target cells of interest for the evaluation of biological relevance of genetic variants (natural occurring or edited via TALEN) on the cellular phenotype

          • In vivo biology in transgenic animal models – via TALEN-modified animal models (genome-editing; modification of the genetic background by natural occurring human genetic variations of interest in small and/or large animal models)

          • Quantification of gene variant function in volunteers - access to human iPS cells from genetically/phenotypically defined patients, eQTL-analyses in tissues of interest (heart, vessel, monocytes)

          • Development of diagnostic tools (genetic tests) for SNPs etc., Customized SNP arrays, MiSeq./ Sequencing





          We are interested in the following formulation developments, delivery technologies and applications to support our research in various indications

          Formulation development:
            • Protein formulation

            • High concentration monoclonal antibodies

            • Modelling of drying processes

            • Novel excipients

            • Prefilled syringe / patch pumps

            • Ex vivo simulation of protein administration

            • Subcutaneous application

            • Antibody drug conjugates

            • Immunoconjugates

            • Mechanistic understanding of proteinaceous particle formation

            • Lyophilisate technology

            • Stability – improvement for sensitive drugs

            • Solubility enhancement

            • Particles in parenterals (analytical characterisation, formation processes, how to avoid them)

            • Release modelling of polymeric implants

            • Alternative polymers for sustained release

            • Aerosol, dry powder, microparticles, nebulizer

            • Inhalative formulations & application

            • Intranasal formulation & application

            • Excipients

            • New agglomeration technologies

            • New granulation technologies

            • New coating technologies

            • Technology - nanosizing

            • New tableting technology

            • Amorphous systems

            • Nanocrystals

            • Controlled release systems

            • Modified release systems

            • Continuous pharmaceutical manufacturing

            • ElectroNanospray

            • Biorelevant dissolution models

            • Methods for improved solubilisation

            • 3D printed tablets

            • 3D printed devices

            • E-health applications

            • Liquid aerosol application

            • Dry powder application

            • Intranasal application

            • Biosensor (hormone, oncological / cardiological biomarker)

            • Non thermic radiation impact on drugs (bluetooth)

            • Dry powder inhalation / inhaler

            • Aerosolization / nebulizer for inhalation

            • Spray pumps for nasal application (stand alone systems and fixed combinations – e.g. pump on bottle)

            Anything else in your pipeline?
            Check out what indications we are interested in